PremiumCompany AnnouncementsPYC Therapeutics Announces Change in Substantial Shareholder Interests PYC Therapeutics Reports Positive Clinical Trial Results for Eye Disease Treatment PYC Therapeutics Advances Towards Commercial Stage with Extended Funding PremiumCompany AnnouncementsPYC Therapeutics Updates Investors on Business Progress Buy Rating for PYC Therapeutics: Promising Pipeline and Market Position in Genetic Medicine PYC Therapeutics Completes Retail Entitlement Offer, Raising $9.3 Million PremiumCompany AnnouncementsPYC Therapeutics Announces Retail Entitlement Offer PYC Therapeutics Secures $146 Million to Advance Drug Pipeline PYC Therapeutics Launches A$145.8 Million Entitlement Offer